DERM Dermira, Inc.

+0  (1%)
Previous Close 34.16
Open 34.11
Price To book 4.92
Market Cap 1.23B
Shares 35,675,000
Volume 246,692
Short Ratio 11.04
Av. Daily Volume 323,258

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data from first trial released October 2016 - endpoints met. Second trial data released December 8, 2016 - endpoints met. Data from third and final trial met primary endpoint - January 19, 2017. FDA filing due 3Q 2017.
Moderate-to-severe plaque psoriasis
Phase 3 trial initiation announced January 3, 2017. Data are due 1H 2018.
Olumacostat glasaretil (DRM01)
Phase 3 data released June 2016. NDA Filing 2H 2017.
Glycopyrronium tosylate (DRM04)
Primary axillary hyperhidrosis

Latest News

  1. Xenon Pharma Dumps Acne Drug After Study Failure
  2. Novartis’ Cosentyx Shows Psoriasis Modification Potential (NVS, DERM)
  3. Dermira Presents New Data Highlighting Patient Outcomes in Axillary Hyperhidrosis at Maui Derm Meeting
  4. Dermira to Highlight Data for Three Clinical Programs at Annual Maui Derm Meeting
  5. Coverage initiated on Dermira by Raymond James
  6. Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  7. DERMIRA, INC. Financials
  8. New CIMZIA® (certolizumab pegol) data in moderate-to-severe plaque psoriasis and psoriatic arthritis presented at American Academy of Dermatology 2017 Annual Meeting
  9. Dermira Presents New Data in Primary Axillary Hyperhidrosis and Acne at American Academy of Dermatology 2017 Annual Meeting
  10. Dermira to Present at Cowen and Company 37th Annual Health Care Conference
  11. Dermira, Inc. :DERM-US: Earnings Analysis: 2016 By the Numbers : March 2, 2017
  12. DERMIRA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and
  13. Dermira Prices $168.5 Million Public Offering of Common Stock
  14. DERMIRA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements a
  15. Dermira reports 4Q loss
  16. Dermira reports 4Q loss
  17. Dermira Announces Proposed Public Offering of Common Stock
  18. DERMIRA, INC. Files SEC form 10-K, Annual Report
  19. Dermira Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
  20. Q4 2016 Dermira Inc Earnings Release - After Market Close